title: Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes.
abstract: Infection with high-risk human papillomavirus (HPV) is necessary for the development of a cervical lesion, but only a fraction of precursor lesions progress to cancer. Additional factors, other than HPV type per se, are likely to increase the probability for progression. Intratype genome variations have been reported to be associated with viral persistence and the development of a major cervical disease. We have recently shown that the prevalence of specific HPV16-E6 variants in invasive cervical cancer (ICC) varies between Italian and Swedish women. To extend our initial study we have analyzed E6 variants in cervical lesions from Czech women, ranging from low-grade cervical intraepithelial neoplasia (LCIN) to ICC and scaled up the sample size of our initial study of Swedish and Italian women. In addition, we have correlated the cases of cancers with human leukocyte antigen (HLA) class II haplotypes. In line with our earlier observation, the distribution of specific HPV16-E6 genotypes in CIN and ICC varied in the 3 cohorts. For instance, the HPV16-E6 L83V variant, which has been found to be positively associated with ICC in Swedish women (p = 0.002), was more prevalent in LCIN than in ICC in Italian and Czech women (p = 0.01 and = 0.03, respectively). These data indicate that host genetic factors, such as HLA polymorphism, may determine the potential oncogenicity of the HPV16-E6 L83V variant. Indeed, the DR04-DQ03 haplotype, which is approximately 3-fold more abundant in the normal Swedish population than in those in Italy and the Czech Republic, was found to be positively associated with HPV16-E6 L83V in the 3 cohorts investigated (p = 0.01). This observation may explain why L83V is a risk factor more in Sweden than in the other 2 countries.
authors.affiliation: Angewandte Tumorvirologie, Deutsches Krebsforschungszentrum, Heidelberg, Germany.
authors.forename: I
authors.initials: I
authors.lastname: Zehbe
authors.forename: R
authors.initials: R
authors.lastname: Tachezy
authors.forename: J
authors.initials: J
authors.lastname: Mytilineos
authors.forename: G
authors.initials: G
authors.lastname: Voglino
authors.forename: I
authors.initials: I
authors.lastname: Mikyskova
authors.forename: H
authors.initials: H
authors.lastname: Delius
authors.forename: A
authors.initials: A
authors.lastname: Marongiu
authors.forename: L
authors.initials: L
authors.lastname: Gissmann
authors.forename: E
authors.initials: E
authors.lastname: Wilander
authors.forename: M
authors.initials: M
authors.lastname: Tommasino
mesh_terms: D003430:Cross-Sectional Studies; D018153:Czech Republic; D005260:Female; D005802:Genes, MHC Class II; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D007558:Italy; D009856:Oncogene Proteins, Viral / Q000235:genetics; D050725:Papillomavirus E7 Proteins; D011110:Polymorphism, Genetic; D012097:Repressor Proteins; D013548:Sweden; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000821:virology*
chemical_list: C068651:E6 protein, Human papillomavirus type 16; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D012097:Repressor Proteins; C059731:oncogene protein E7, Human papillomavirus type 16